B. Wiman

发表

PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION

M. Blombäck, A. Hamsten, U. Faire, 1987, The Lancet.

On the kinetics of the reaction between human antiplasmin and a low-molecular-weight form of plasmin.

B. Wiman, L. Boman, D. Collen, 1978, European journal of biochemistry.

On the kinetics of the reaction between human antiplasmin and plasmin.

B. Wiman, D. Collen, D. Collen, 1978, European journal of biochemistry.

On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin.

B. Wiman, D. Collen, 1979, The Journal of biological chemistry.

On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen.

B. Wiman, D. Collen, H. Lijnen, 1979, Biochimica et biophysica acta.

Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions.

B. Wiman, J. Chmielewska, M. Rånby, 1988, The Biochemical journal.

Stability of Plasminogen Activator Inhibitor 1 (PAI-1)

O. Sigurdardottir, T. Lindahl, B. Wiman, 1989, Thrombosis and Haemostasis.

Stability of plasminogen activator inhibitor‐1: role of tyrosine221

B. Wiman, G. Sui, 1998, FEBS letters.

Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule.

B. Wiman, G. Sui, 1998, The Biochemical journal.

On the structure of the stable complex between plasmin and α2‐antiplasmin

B. Wiman, T. K. Nilsson, T. Nilsson, 1982 .

The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells.

A. Henney, A. Hamsten, B. Wiman, 1993, The Journal of biological chemistry.

Association of apolipoprotein E genotypes with lipid levels and coronary risk.

Bernard Keavney, John Danesh, Anders Ahlbom, 2007, JAMA.

Molecular mechanism of physiological fibrinolysis

B. Wiman, D. Collen, 1978, Nature.

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

M. Blombäck, A. Hamsten, U. de Faire, 1985, The New England journal of medicine.

On the reaction of plasmin or plasmin-streptokinase complex with aprotinin or α2-antiplasmin

B. Wiman, 1980 .

[32] Human α2-antiplasmin☆

B. Wiman, 1981 .

New receptor for human plasminogen on gram positive cocci

B. Wiman, G. Kronvall, M. Ullberg, 1989, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function.

A. Hamsten, U. de Faire, U. Faire, 1998, European heart journal.

Haemostatic Factors and Inhibitors and Coronary Artery Bypass Grafting: Preoperative Alterations and Relations to Graft Occlusion

M. Blombäck, L. Rydén, A. Hamsten, 1994, Thrombosis and Haemostasis.

Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein.

A. Hamsten, B. Wiman, J. Nilsson, 1990, Arteriosclerosis.

Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects

M. Blombäck, B. Wiman, H. Pelzer, 1993, Acta anaesthesiologica Scandinavica.

Impaired fibrinolysis and risk of thromboembolism.

A. Hamsten, B. Wiman, Bjijrn Wiman, 1991, Progress in cardiovascular diseases.

The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene

B. Wiman, S. Schulman, N. Egberg, 1999, Thrombosis and Haemostasis.

Evaluation of low PAI‐1 activity as a risk factor for hemorrhagic diathesis

J. Odeberg, B. Wiman, S. Schulman, 2006, Journal of thrombosis and haemostasis : JTH.

The fibrinolytic enzyme system. Basic principles and links to venous and arterial thrombosis.

B. Wiman, 2000, Hematology/oncology clinics of North America.

Detection of a new polymorphism in the PAI-1 gene located in the pro-peptide coding region

B. Wiman, S. Schulman, G. Falk, 1999 .

Predictive value of fibrinolytic factors in coronary heart disease.

B. Wiman, 1999, Scandinavian journal of clinical and laboratory investigation. Supplementum.

4G/5G Polymorphism of PAI-1 Gene Promoter and Fibrinolytic Capacity in Patients with Deep Vein Thrombosis

B. Wiman, A. Girolami, F. Dazzi, 1998, Thrombosis and Haemostasis.

Identification of an 18 basepair deletion in the PAI-1 gene promoter region in a family with thrombotic disease

B. Wiman, A. Girolami, S. Vettore, 1997 .

The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator.

T. Lindahl, P. Ohlsson, B. Wiman, 1990, The Biochemical journal.

Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene

B. Wiman, G. Falk, Å. Almqvist, 1995 .

Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.

A. Ahlbom, B. Wiman, U. Defaire, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm.

C. Held, P. Hjemdahl, N. Rehnqvist, 2000, Atherosclerosis.

Soluble fibrin: A predictor for the development and outcome of multiple organ failure

M. Blombäck, B. Wiman, S. Bredbacka, 1994, American journal of hematology.

Oxidative stress and release of tissue plasminogen activator in isolated rat hearts.

B. Wiman, G. Valen, J. Vaage, 1997, Thrombosis research.

Release of tissue plasminogen activator during reperfusion after different times of ischaemia in isolated, perfused rat hearts.

B. Wiman, G. Valen, J. Vaage, 1996, Thrombosis research.

Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.

B. Wiman, J. Chmielewska, M. Rånby, 1983, Thrombosis research.

Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study In Stockholm (APSIS). A comparison with healthy controls

C. Held, P. Hjemdahl, B. Angelin, 1997, Journal of internal medicine.

Increased expression of α‐enolase in c‐jun transformed rat fibroblasts without increased activation of plasminogen

K. Sakaguchi, E. Appella, H. Jörnvall, 1997, FEBS letters.

The role of the fibrinolytic system in deep vein thrombosis.

M. Blombäck, B. Wiman, B. Ljungberg, 1985, The Journal of laboratory and clinical medicine.

Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity

B. Wiman, S. Schulman, A. Ågren, 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Determination of tissue plasminogen activator and its "fast" inhibitor in plasma.

B. Wiman, J. Chmielewska, 1986, Clinical chemistry.

altered levels of plasma plasminogen activator inhibitor-1 activity Genetic variation at the plasminogen activator inhibitor-1 locus is associated with

A. Hamsten, B. Wiman, S. Humphries, 2011 .

Possibilities of DNA Analysis for the Detection of Predisposition to Thrombotic Disease

S. Humphries, A. Hamsten, P. Brennan, 1992, Annals of the New York Academy of Sciences.

Genetic variation at the plasminogen activator inhibitor-1 (PAI-1) locus

A. Hamsten, B. Wiman, S. Humphries, 1990 .

α and β-adrenergic influences on the tissue and urokinase plasminogen activator systems

P. T. Larsson, G. Dooijewaard, B. Wiman, 1999 .

The Fibrinolytic Enzyme System and Its Role in the Etiology of Thromboembolic Disease

A. Hamsten, B. Wiman, 1990, Seminars in thrombosis and hemostasis.

Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor.

B. Wiman, J. Chmielewska, M. Rånby, 1984, The Journal of biological chemistry.

Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma: Its Role in Thrombotic Disease

B. Wiman, 1995, Thrombosis and Haemostasis.

Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes.

B. Wiman, A. Nordenhem, 1998, Scandinavian journal of clinical and laboratory investigation.

The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen.

B. Wiman, P. Wallén, Per Wallén, 1977, Thrombosis research.

Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma.

B. Wiman, D. Collen, D. Collen, 1977, European journal of biochemistry.

Binding of tissue-type plasminogen activator (t-PA) to Neisseria meningitidis and Haemophilus influenzae.

B. Wiman, G. Kronvall, M. Ullberg, 1994, FEMS immunology and medical microbiology.

Two types of receptors for human plasminogen on group G streptococci

B. Wiman, G. Kronvall, M. Ullberg, 1992, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Receptors for human plasminogen on gram-negative bacteria

B. Wiman, G. Kronvall, M. Ullberg, 1990, Infection and immunity.

Haemostatic function in myocardial infarction.

A. Hamsten, U. Faire, J. Svensson, 1986, British heart journal.

Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction.

A. Bennet, J. Prince, U. Faire, 2003, Atherosclerosis.

Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction.

U. de Faire, U. Yasar, A. Bennet, 2003, Pharmacogenetics.

Amino‐acid sequence of human α2‐antiplasmin

B. Wiman, D. Collen, H. Lijnen, 1987 .

Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma.

B. Wiman, D. Collen, 1979, Blood.

Amino-acid sequence of human a2-antiplasmin

B. Wiman, H. Lijnen, D. Collen, 1987 .

Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma

O. Sigurdardottir, T. Lindahl, B. Wiman, 1988, FEBS letters.

Evidence for a Discrete Binding Protein of Plasminogen Activator Inhibitor in Plasma

T. Lindahl, B. Wiman, Å. Almqvist, 1988, Thrombosis and Haemostasis.

On the Relationship Between Different Molecular Forms of the Fast Inhibitor of Tissue Plasminogen Activator

B. Wiman, J. Chmielewska, G. Urdén, 1987 .

A new simple method for determination of C1-esterase inhibitor activity in plasma.

B. Wiman, T. Nilsson, 1983, Clinica chimica acta; international journal of clinical chemistry.

Correlations between fibrinolytic function and acute myocardial infarction.

A. Hamsten, B. Wiman, Anders Hamsten, 1990, The American journal of cardiology.

Comparison of plasminogen activator inhibitor activity and antigen in plasma samples.

A. Hamsten, B. Wiman, G. Urdén, 1987, Clinica chimica acta; international journal of clinical chemistry.

PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction: results from the Stockholm Heart Epidemiology Program (SHEEP).

U. de Faire, K. Leander, B. Wiman, 2003, Thrombosis and haemostasis.

Effects of plasma kallikrein and bradykinin infusions into pigs on plasma fibrinolytic variables and urinary excretion of thromboxane and prostacyclin metabolites

B. Wiman, N. Egberg, K. Gréen, 1988 .

Inactivation of antiplasmin at low pH: evidence for the formation of latent molecules.

B. Wiman, Haiyao Wang, S. Pap, 2004, Thrombosis research.

Structures of importance for the stability of antiplasmin as studied by site-directed mutagenesis.

B. Wiman, Haiyao Wang, S. Pap, 2006, Thrombosis research.

Plasminogen activator inhibitor-1 (PAI-1) content in platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene.

B. Wiman, A. Nordenhem, 1997, Scandinavian journal of clinical and laboratory investigation.

The Significance of Hypofibrinolysis for the Risk of Recurrence of Venous Thromboembolism

B. Wiman, S. Schulman, 1996, Thrombosis and Haemostasis.

Enzymatic properties of t-PA/α2-macroglobulin complexes

B. Wiman, M. Haegerstrand-Björkman, S. Perge, 1991 .

Thrombolysis and fibrinolytic parameters during heparin treatment of deep vein thrombosis.

B. Wiman, S. Schulman, S. Granqvist, 1985, Thrombosis research.

Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistance

M. Blombäck, B. Wiman, M. Bokarewa, 1997, European journal of clinical investigation.

The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project.

U. de Faire, K. Leander, B. Wiman, 2005, Thrombosis research.

A novel fast inhibitor to tissue plasminogen activator in plasma, which may be of great pathophysiological significance.

B. Wiman, J. Chmielewska, 1985, Scandinavian journal of clinical and laboratory investigation. Supplementum.

Immunological Relationship Between Plasminogen Activator Inhibitors from Different Sources

B. Wiman, J. Chmielewska, G. Urdén, 1987, Thrombosis and Haemostasis.

Determination of Soluble Fibrin in Plasma by a Rapid and Quantitative Spectrophotometric Assay

B. Wiman, M. Rånby, 1986, Thrombosis and Haemostasis.

Plasminogen activator release during venous stasis and exercise as determined by a new specific assay.

B. Wiman, M. Rånby, G. Mellbring, 1983, Clinica chimica acta; international journal of clinical chemistry.

Stimulation of F-Cell Production in Patients with Sickle-Cell Anemia Treated with Cytarabine or Hydroxyurea 1571

M. Blombäck, A. Hamsten, U. Faire, 1985 .

The G-455A polymorphism of the fibrinogen Bbeta-gene relates to plasma fibrinogen in male cases, but does not interact with environmental factors in causing myocardial infarction in either men or women : Journal of Internal Medicine

K. Leander, U. Faire, B. Wiman, 2002 .

Affinity-chromatographic purification of human α2-antiplasmin

B. Wiman, 1980 .

A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.

B. Wiman, M. Holmström, M. Karlman, 2011, Thrombosis research.

Proceedings: Purification of tissue activator using affinity adsorption on fibrin and hydrophobic interaction chromatography. Effect of fibrin on the enzymatic properties of the activator.

B. Wiman, P. Wallén, 1975, Thrombosis et diathesis haemorrhagica.

Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen.

B. Wiman, P. Wallén, 1972, Biochimica et biophysica acta.

Fibrinolytic activity in plasma and deep vein thrombosis after major abdominal surgery.

B. Wiman, S. Reiz, G. Mellbring, 1983, Thrombosis research.

Influence of Metoprolol Treatment on Sympatho-Adrenal Activation of Fibrinolysis

P. T. Larsson, P. Hjemdahl, B. Angelin, 1990, Thrombosis and Haemostasis.

The interaction between plasminogen and antiplasmin variants as studied by surface plasmon resonance.

B. Wiman, A. Karlsson, Haiyao Wang, 2006, Biochimica et biophysica acta.

Relationship between preoperative status of the fibrinolytic system and occurrence of deep vein thrombosis after major abdominal surgery.

B. Wiman, G. Mellbring, O. Sunnegårdh, 1985, Thrombosis research.

Purification and characterization of human C1-esterase inhibitor.

B. Wiman, T. K. Nilsson, T. Nilsson, 1982, Biochimica et biophysica acta.

Coagulation Factor V (Arg506 → Gln) Mutation and Early Saphenous Vein Graft Occlusion after Coronary Artery Bypass Grafting

M. Blombäck, L. Rydén, A. Hamsten, 1998, Thrombosis and Haemostasis.

The Fast Inhibitor of Tissue Plasminogen Activator in Plasma During Pregnancy

B. Wiman, G. Csemiczky, L. Marsk, 1984, Thrombosis and Haemostasis.

Primary structure of peptides released during activation of human plasminogen by urokinase.

B. Wiman, 1973, European journal of biochemistry.

Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound.

B. Wiman, P. Wallén, 1973, European journal of biochemistry.

Association of TNF-alpha serum levels and TNFA promoter polymorphisms with risk of myocardial infarction.

U. de Faire, A. Bennet, J. Prince, 2006, Atherosclerosis.

Characterization of human plasminogen. I. On the relationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparations.

B. Wiman, P. Wallén, Per Wallén, 1970, Biochimica et biophysica acta.

The physiological inhibitors of blood coagulation and fibrinolysis : proceedings of a round-table conference held at the University of Leuven, Belgium, July 22-23, 1978

B. Wiman, M. Verstraete, D. Collen, 1979 .

Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate.

B. Wiman, S. Schulman, A. Ågren, 2007, Thrombosis Research.

Plasma fibrinolytic activity in patients undergoing major abdominal surgery.

B. Wiman, G. Mellbring, S. Dahlgren, 1985, Acta chirurgica Scandinavica.

Primary structure of the B-chain of human plasmin.

B. Wiman, 1977, European journal of biochemistry.

Structural relationship between "glutamic acid" and "lysine" forms of human plasminogen and their interaction with the NH2-terminal activation peptide as studied by affinity chromatography.

B. Wiman, P. Wallén, Per Wallén, 1975, European journal of biochemistry.

On the primary structure of human plasminogen and plasmin. Purification and characterization of cyanogen-bromide fragments.

B. Wiman, P. Wallén, 1975, European journal of biochemistry.

On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin.

B. Wiman, D. Collen, I. Rákóczi, 1978, Biochimica et biophysica acta.

Amino-acid sequence of the cyanogen-bromide fragment from human plasminogen that forms the linkage between the plasmin chains.

B. Wiman, P. Wallén, 1975, European journal of biochemistry.

On the structure of the N-terminal fragment of human plasminogen obtained after cleavage with cyanogen bromide

B. Wiman, 1972 .

Amino acid sequence around the arginyl-valyl bond in plasminogen which is cleaved during the second step of the activation process.

B. Wiman, P. Wallén, 1975, Thrombosis research.

Identification of amino acids in antiplasmin involved in its noncovalent 'lysine-binding-site'-dependent interaction with plasmin.

B. Wiman, A. Yu, Haiyao Wang, 2003, European journal of biochemistry.

Criteria for the Specific Measurement of Plasmin Inhibitor Activity Using an Enzymatic Procedure.

B. Wiman, P. Meijer, M. Hanss, 2001, EJIFCC.

Acute effects with reference to thrombogenicity and liver toxicity after injection of different coagulation factor concentrates.

B. Wiman, S. Schulman, H. Johnsson, 1989, Haemostasis.

Preparation and isolation of the S‐carboxymethyl derivative chains of human fibrinogen

M. Blombäck, B. Wiman, B. Blombäck, 1971, FEBS letters.

Affinity-chromatographic purification of human alpha 2-antiplasmin.

B. Wiman, 1980, The Biochemical journal.

ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation

G. Auer, S. Linder, M. Seddighzadeh, 2004, Clinical & Experimental Metastasis.

Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope.

U. de Faire, A. Bennet, J. Prince, 2004, Arthritis and rheumatism.

Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the S heep study

C. Hogstedt, A. Wolk, C. Hogstedt, 1999 .

Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study. The SHEEP Study Group.

A Ahlbom, F Diderichsen, C Hogstedt, 1999, Journal of internal medicine.

Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-β1-42 and plasma apolipoprotein levels

K. Blennow, A. Brookes, A. Bennet, 2006, Journal of Human Genetics.

Haplotypes extending across ACE are associated with Alzheimer's disease.

L. Feuk, K. Blennow, N. Cairns, 2003, Human molecular genetics.

Molecular Mechanisms of Fibrinolysis in Man

F. Castellino, B. Wiman, D. Collen, 1978, Thrombosis and Haemostasis.

Antiplasmin, the Fast-Reacting Plasmin Inhibitor of Human Plasma

B. Wiman, D. Collen, 1977, Thrombosis and Haemostasis.

Fast-acting plasmin inhibitor in human plasma.

B. Wiman, D. Collen, 1978, Blood.

Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization.

R. Huber, E. Nielsen, R. Eddy, 1986, Biochemistry.

Studies on a form of alpha 2-antiplasmin in plasma which does not interact with the lysine-binding sites in plasminogen.

B. Wiman, T. Nilsson, B. Cedergren, 1982, Thrombosis research.

Fibrinolytic response after injection of desamino-d-arginine vasopressin (dDAVP) in healthy volunteers

B. Wiman, N. Egberg, G. Bratt, 1992 .

Soluble fibrin in plasma as a sign of activated coagulation in patients with pregnancy complications

B. Wiman, K. Bremme, E. Östlund, 1998, Acta obstetricia et gynecologica Scandinavica.

Haemostatic function in myocardial infarction.

M. Blombäck, A. Hamsten, U. de Faire, 1986, British heart journal.

Changes in antigenic structure and conformation of alpha 2-antiplasmin induced by interaction with plasmin.

B. Wiman, E. Plow, D. Collen, 1980, The Journal of biological chemistry.

The Non-covalent interaction between plasmin and α2-antiplasmin

B. Wiman, M. Rånby, Å. Almgvist, 1989 .

Kinetics of the reaction between human C1-esterase inhibitor and C1r or C1s.

B. Wiman, T. Nilsson, 2005, European journal of biochemistry.

Partial Primary Structure of Human α2-Antiplasmin – Homology with Other Plasma Protease Inhibitors

B. Wiman, D. Collen, H. Lijnen, 1982, Thrombosis and Haemostasis.

Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility

Per Eriksson, Ulf de Faire, Jacob Lagercrantz, 2005, Nature Genetics.

Increased Incorporation of Antiplasmin Into the Fibrin Network in Patients With Type 1 Diabetes

G. Elgue, B. Wiman, P. Henriksson, 2014, Diabetes Care.

Purification and characterization of human C1-esterase inhibitor.

B. Wiman, T. Nilsson, 1982, Biochimica et biophysica acta.

The association between fibrinogen haplotypes and myocardial infarction in men is partly mediated through pleiotropic effects on the serum IL‐6 concentration

A. Hamsten, A. Silveira, U. de Faire, 2007, Journal of internal medicine.

Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men

A. Hamsten, B. Wiman, L. Carlson, 1993, Diabetologia.

No effect of factor Xa or tissue thromboplastin and factor VII on the activation of plasminogen.

H. Prydz, B. Wiman, T. Holm, 1976, Thrombosis research.

Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction.

A. Hamsten, P. Eriksson, U. de Faire, 2004, European heart journal.

PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction

U. de Faire, K. Leander, B. Wiman, 2003, Thrombosis and Haemostasis.

Decreased risk for myocardial infarction and lower tumor necrosis factor-alpha levels in carriers of variants of the PDCD1 gene.

L. Prokunina-Olsson, U. de Faire, A. Bennet, 2006, Human immunology.

Inactivation of tissue plasminogen activator in plasma

B. Wiman, 1988 .

Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm.

C. Held, P. Hjemdahl, Sven Eriksson, 1997, Circulation.

Purification of high and low molecular weight plasminogen activator inhibitor 1 from fibrosarcoma cell-line HT 1080 conditioned medium.

T. Lindahl, B. Wiman, 1989, Biochimica et biophysica acta.

Monoclonal Antibodies Towards the Fast Inhibitor of Tissue Plasminogen Activator from Human Plasma and Serum

B. Wiman, J. Chmielewska, J. Brandt, 1986, Thrombosis and Haemostasis.

A coagulo-radioimmunometric assay for the quantitation of fibrin monomer in human plasma. Principles and development of the method.

Jordi Félez, B. Wiman, E. Plow, 1979, Thrombosis research.

Primary risk factors influence risk of recurrent myocardial infarction/death from coronary heart disease: results from the Stockholm Heart Epidemiology Program (SHEEP)

A. Ahlbom, U. de Faire, K. Leander, 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity.

A. Henney, A. Hamsten, B. Wiman, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

A COACLZO-lUDIOIMMUNOMBTRIC ASSAY FOR THE QUANTITXTION OF FIBRIN MONOMER IN HDMAN PLASMA. PRINCIPLES AND DEVELOPZNT OF THE METHOD

B. Wiman, D. Collen, 1979 .

The G‐455A polymorphism of the fibrinogen BΒ‐gene relates to plasma fibrinogen in male cases, but does not interact with environmental factors in causing myocardial infarction in either men or women

U. de Faire, K. Leander, B. Wiman, 2002, Journal of internal medicine.

Haemostatic function in patients undergoing coronary artery bypass grafting: peroperative perturbations and relations to saphenous vein graft closure.

M. Blombäck, L. Rydén, A. Hamsten, 2000, Thrombosis research.

Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels.

P. Hjemdahl, M. Eriksson, B. Angelin, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.

U. de Faire, U. Yasar, A. Bennet, 2002, Biochemical and biophysical research communications.

A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity.

K. Blennow, B. Lenhard, P. Kehoe, 2004, Human molecular genetics.

Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: a HuGE association review and meta-analysis.

J. Danesh, U. de Faire, J. Higgins, 2008, American journal of epidemiology.

Complex formation between plasminogen activator inhibitor 1 and vitronectin in purified systems and in plasma.

O. Sigurdardottir, B. Wiman, 1990, Biochimica et biophysica acta.

Determination of plasmin-alpha 2-antiplasmin complex in plasma samples by means of a radioimmunoassay.

M. Andersson, B. Wiman, G. Mellbring, 1983, Scandinavian journal of clinical and laboratory investigation.

PAI‐1 stability: the role of histidine residues

B. Wiman, G. Sui, H. Mångs, 2000, FEBS letters.

The Bβ-sheet in the PAI-1 Molecule Plays an Important Role for Its Stability

B. Wiman, G. Sui, 2000, Thrombosis and Haemostasis.

Identification of a PAI-1 binding site in vitronectin.

O. Sigurdardottir, B. Wiman, Björn Wiman, 1994, Biochimica et biophysica acta.

Genetic factors determining thrombosis and fibrinolysis.

S. Humphries, A. Hamsten, B. Wiman, 1992, Annals of epidemiology.

Plasminogen activator inhibitor 1 in thrombotic disease

B. Wiman, 1996, Current opinion in hematology.

Enhancement of t-PA-mediated plasminogen activation by bacterial surface receptors

B. Wiman, G. Kronvall, M. Ullberg, 1995 .

Prediction of deep vein thrombosis after extensive abdominal operations by the quotient between plasmin-alpha 2-antiplasmin complex and fibrinogen concentration in plasma.

B. Wiman, G. Mellbring, S. Dahlgren, 1985, Surgery, gynecology & obstetrics.

The role of His143 for the pH-dependent stability of plasminogen activator inhibitor-1

B. Wiman, G. Sui, H. Mångs, 1999 .

The role of His(143) for the pH-dependent stability of plasminogen activator inhibitor-1.

B. Wiman, G. Sui, H. Mångs, 1999, Biochimica et biophysica acta.

Association of TNF-α serum levels and TNFA promoter polymorphisms with risk of myocardial infarction

A. Bennet, J. Prince, U. Faire, 2006 .

Low PAI‐1 activity in relation to inflammatory parameters, insulin profile and body mass index

B. Wiman, S. Schulman, A. Ågren, 2008, Journal of internal medicine.

Circular dichroism studies on α2-antiplasmin and its interactions with plasmin and plasminogen

B. Wiman, I. Sjöholm, T. Nilsson, 1982 .

Association of Apolipoprotein E Genotypes With Lipid Levels and Coronary Risk

J. Danesh, R. Collins, A. Ahlbom, 2007 .

Association of apolipoprotein E genotypes with lipid levels and coronary risk.

J. Danesh, R. Collins, A. Ahlbom, 2007, JAMA.

Human fibrinogen: Some characteristics of its S-carboxymethyl derivative chains☆

B. Wiman, B. Blombäck, G. Murano, 1972 .

Modification of a tyrosine residue in the carboxyterminal portion of human alpha2-antiplasmin.

B. Wiman, D. Collen, H. Lijnen, 1985, Thrombosis research.

Effects of the synthetic fibrinolytic agents ortho-thymotic acid and S-1623 on the reaction between human plasmin and antiplasmin.

B. Wiman, M. Samama, D. Collen, 1978, Thrombosis research.

Studies on the conformational changes of plasminogen induced during activation to plasmin and by 6-aminohexanoic acid.

B. Wiman, I. Sjöholm, Per Walléan, 1973, European journal of biochemistry.